Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$4.02 USD
+0.28 (7.49%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $3.88 -0.14 (-3.48%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 221 - 240 ( 446 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR II 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
For iPSC-Derived NK Cells, the Time Is Nigh With 4Q20 Poised to Provide Platform Validation; Initiating With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20: Fate Puts Another New Drug in the Clinic and Advances the Rest
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Earnings; Preclinical Updates at ASGCT and AACR, the Sequel
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 27 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of the ASGCT 2020 Virtual Meeting - Read Through To Our Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 13 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D